Does Metoprolol Cause Hair Loss?

What the Metoprolol Evidence Actually Shows

The metoprolol succinate prescribing information includes reversible alopecia among reactions reported after approval. That section covers extended-release and immediate-release metoprolol. It also explains that reports come from a population of uncertain size, so their frequency and causal relationship cannot always be determined. A report count is not an incidence rate: it lacks a reliable denominator of people taking the drug.

Graeber and Lapkin's 1981 report, Metoprolol and alopecia, describes one reversible case with telogen effluvium on biopsy. A single case can identify a possible adverse effect. It cannot tell us how often it occurs, predict an individual's outcome or rank metoprolol against other beta-blockers.

These two sources answer different questions. The label establishes that hair loss has been reported; the case documents a compatible shedding pattern. Neither supports a claim that 1% to 5% of users lose hair.

Recognizing the Pattern and Timing

Malkud's review of telogen effluvium describes diffuse, nonscarring shedding that can appear a few months after a trigger. Illness, surgery, nutritional problems, thyroid disorders and medicines can all be relevant. That delayed hair-cycle response explains why the important event may precede the shedding by months.

The timing is a clue, not a diagnostic test. Someone who starts metoprolol after a serious illness may have more than one plausible trigger. Record the medicine start or dose-change date, the first noticeable shedding and intervening illness or dietary changes. A scalp examination can distinguish shedding from patterned thinning, patches or hair breakage; tests depend on the history and findings.

Succinate, Tartrate, Dose and Other Beta-Blockers

The label includes reports from both extended-release and immediate-release metoprolol. It does not provide a hair-loss comparison between formulations or doses. Switching release forms cannot be promised to resolve shedding.

The case report also mentions prior reports with propranolol. This does not mean every beta-blocker causes hair loss in every user. The sources here cannot identify a least-risk beta-blocker or justify a table of comparative reporting odds. Choosing an alternative requires the original cardiac indication to remain treated.

Discussing a Medication Change

Bring the timeline and a complete medicine and supplement list to the prescriber. The practical question is whether metoprolol is the most plausible trigger after other explanations have been assessed, and whether a different treatment fits the condition being treated. Blood pressure treatment, heart-failure treatment and heart-rate control do not have identical substitution options.

The prescribing information cautions against abrupt withdrawal. It describes gradual dose reduction over one to two weeks when chronic treatment is discontinued, with monitoring. That is a prescriber-managed change, not a self-directed taper for suspected hair loss.

Iron, Supplements and Hair Treatments

Iron deficiency is one possible explanation to investigate, but one ferritin result does not establish metoprolol as the cause. Dr. Wilma Bergfeld coauthored Trost, Bergfeld and Calogeras's iron-deficiency review. It found insufficient evidence for universal iron screening of everyone with hair loss or routine iron treatment for hair loss with iron deficiency but without anemia. This supports evaluating the individual rather than prescribing a fixed iron dose or universal ferritin target.

Dr. Lynne Goldberg and Yolanda Lenzy authored Nutrition and hair, a review of nutritional issues in hair disease. These are published scholarly contributions, rather than personal recommendations about switching a particular patient's beta-blocker.

Minoxidil is not established by the metoprolol case report as a treatment for this adverse effect. A study of patterned hair loss would not, by itself, show that minoxidil accelerates recovery from metoprolol-related shedding. Discuss whether there is a separate hair-loss diagnosis and which treatment fits it instead of adding a standard combination regimen.

Biotin is also not established by these metoprolol sources as a remedy. The FDA's biotin and troponin information describes interference with certain laboratory tests. Include biotin on the supplement list shared before testing.

Recovery and Persistent Thinning

The published metoprolol case was reversible. That does not guarantee that all thinning in a person taking metoprolol will reverse after a switch. General telogen effluvium recovery takes months; another continuing trigger or coexisting patterned hair loss can change the course. Persistent thinning needs reassessment of the diagnosis rather than repeated medication changes based only on the calendar.